Chemical Structure (Calcipotriene Foam 01)
Calcipotriene Aerosol, Foam
Product Images NDC 51862-512
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Calcipotriene (NDC 51862-512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure A (Calcipotriene Foam 02)
Figure B (Calcipotriene Foam 03)
Figure C (Calcipotriene Foam 04)
Figure D (Calcipotriene Foam 05)
Figure E (Calcipotriene Foam 06)
Figure F (Calcipotriene Foam 07)
Figure G (Calcipotriene Foam 08)
Principal Display Panel (60 grams Can Carton)
This is a medication label for Calcipotriene Foam, which is used topically for psoriasis. The foam contains Calcipotriene, and each gram of foam contains 50 mcg/g calcipotriene. The medication should not be used on the eyes, orally or intravaginally. The instructions indicate that users should shake the can before using and turn it upside down and press firmly to dispense. The foam has a flammable warning, and users should avoid smoking, fire, or flame during and immediately following application. The medication is distributed by Mayne Pharma and is a product of Israel. There is also information regarding dosage, storage, and potential adverse reactions.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
